Helix Nanotechnologies

Two HelixNano employees working in the lab in Cambridge, MA. Photo: HelixNano

HelixNano is a clinical-stage mRNA startup.

HelixNano focuses on empowering creative individuals to follow their curiosity. The RA-level position includes coaching and mentoring to support scientific growth.

Medicus Pharma announces a non-binding memorandum of understanding with Helix Nanotechnologies to develop thermostable infectious disease vaccines. The vaccine development would combine the HelixNano mRNA platform with Medicus's dissolvable microneedle array technology, and the parties are negotiating a potential joint venture.

Aug 2025 · Medicus PharmaNews article

Helix Nanotechnologies announces that its Australian subsidiary, HelixNano Australia, has received HREC approval to initiate a Phase 1 clinical trial. The study evaluates HN-0001, the company’s second-generation COVID mRNA vaccine for immunosuppressed patients, and first dosing is expected in April 2024.

Mar 2024 · EIN PresswireNews article

Helix Nanotechnologies describes a mutation-resistant mRNA booster approach using two patented technologies intended to target antibodies and amplify the immune response. The company plans a trial in 2021 and is collaborating with the University of Pittsburgh on skin delivery.

Mar 2021 · CNBCNews article

Helix Nanotechnologies, a six-person startup founded in 2013, pivots from cancer therapeutics to developing an mRNA vaccine for SARS-CoV-2. Founder Hannu Rajaniemi’s company begins its first mouse injections in April 2020, while working to invent a vaccine amid the pandemic.

Apr 2020 · CNBC Make ItNews article